CECCHI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.136
EU - Europa 5.158
AS - Asia 2.694
SA - Sud America 541
AF - Africa 68
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 2
Totale 15.640
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.048
RU - Federazione Russa 1.632
PL - Polonia 1.563
SG - Singapore 661
CN - Cina 625
HK - Hong Kong 497
BR - Brasile 439
IE - Irlanda 435
IT - Italia 431
SE - Svezia 365
KR - Corea 299
VN - Vietnam 240
DE - Germania 208
UA - Ucraina 148
GB - Regno Unito 126
IN - India 115
FI - Finlandia 101
JO - Giordania 86
CA - Canada 54
ID - Indonesia 52
FR - Francia 46
AU - Australia 41
AR - Argentina 39
ES - Italia 34
JP - Giappone 30
NL - Olanda 27
MA - Marocco 23
MX - Messico 19
TR - Turchia 17
BD - Bangladesh 15
IQ - Iraq 13
CO - Colombia 12
PY - Paraguay 12
RO - Romania 12
EC - Ecuador 11
VE - Venezuela 11
CI - Costa d'Avorio 10
ZA - Sudafrica 8
AE - Emirati Arabi Uniti 7
PK - Pakistan 7
SC - Seychelles 7
BE - Belgio 6
CH - Svizzera 6
PE - Perù 6
AT - Austria 5
CL - Cile 5
DZ - Algeria 5
IR - Iran 5
DO - Repubblica Dominicana 4
EG - Egitto 4
PH - Filippine 4
TN - Tunisia 4
UY - Uruguay 4
UZ - Uzbekistan 4
BW - Botswana 3
CZ - Repubblica Ceca 3
HN - Honduras 3
KE - Kenya 3
CR - Costa Rica 2
CY - Cipro 2
EU - Europa 2
GT - Guatemala 2
IL - Israele 2
KZ - Kazakistan 2
LT - Lituania 2
NO - Norvegia 2
PT - Portogallo 2
SA - Arabia Saudita 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
DK - Danimarca 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MU - Mauritius 1
NI - Nicaragua 1
NP - Nepal 1
PS - Palestinian Territory 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
VG - Isole Vergini Britanniche 1
Totale 15.640
Salva come PNG Salva come JPEG
Città #
Warsaw 1.561
Santa Clara 1.480
Fairfield 836
Ashburn 576
Dublin 434
Singapore 419
Hong Kong 406
Woodbridge 361
Seattle 338
Cambridge 335
Chandler 320
Seoul 293
Houston 288
Wilmington 266
Beijing 244
Jacksonville 243
Ann Arbor 127
Hefei 126
Los Angeles 104
Princeton 103
Lawrence 99
Altamura 95
Buffalo 93
Boston 84
Mumbai 84
Florence 74
Moscow 67
Dallas 63
Ho Chi Minh City 61
Munich 54
Dong Ket 48
Boardman 45
São Paulo 43
San Diego 41
Medford 40
Melbourne 39
Hanoi 38
Jakarta 37
New York 33
Turku 32
San Jose 31
Council Bluffs 30
The Dalles 28
Redondo Beach 27
Shanghai 25
Tokyo 25
Clifton 23
Norwalk 21
Rome 21
Toronto 20
Kent 18
Barcelona 17
Paris 17
Milan 16
Ottawa 16
Phoenix 16
Frankfurt am Main 14
London 13
Rio de Janeiro 13
Casablanca 12
Long Branch 12
Montreal 12
West Jordan 12
Belo Horizonte 11
Abidjan 10
Brasília 10
Da Nang 10
Buenos Aires 9
Lappeenranta 9
Thái Bình 9
Andover 8
Asunción 8
Frankfurt Am Main 8
Guangzhou 8
Hillsboro 8
Izmir 8
St Petersburg 8
Auburn Hills 7
Curitiba 7
Falls Church 7
Haiphong 7
Madrid 7
Nuremberg 7
Orem 7
Prato 7
Amman 6
Biên Hòa 6
Brussels 6
Chennai 6
Chicago 6
Denver 6
Falkenstein 6
Helsinki 6
Jersey City 6
Matlock 6
Naples 6
Sumaré 6
Tianjin 6
Yubileyny 6
Atlanta 5
Totale 10.738
Salva come PNG Salva come JPEG
Nome #
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 303
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 285
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 283
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 278
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 253
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 246
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 245
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 239
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 238
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 229
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 219
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 210
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 201
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 200
CHARACTERISTICS OF MYOCARDIAL HYPERTROPHY IN FRIEDREICH'S ATAXIA. CLINICO-INSTRUMENTAL STUDY IN 10 PATIENTS AND REVIEW OF THE LITERATURE 196
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 193
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 193
Malattia di Anderson-Fabry 192
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 191
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 191
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 190
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol 189
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 183
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 183
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 182
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 182
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 180
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 177
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 173
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 172
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 164
Hypertrophic cardiomyopathy: prevalence of disease-specific red flags 162
HYPERTROPHIC CARDIOMYOPATHY 161
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. 160
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. 160
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 160
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. 159
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 158
ARRHYTHMIAS ASSOCIATED WITH HYPERTROPHIC CARDIOMYOPATHY 156
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 155
Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®) 155
Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy 150
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. 146
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy 146
CLINICAL PROFILE OF STROKE IN 900 PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 145
Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy 145
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression 145
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy 143
Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy 143
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy 143
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 141
Echocardiographic features of right ventricular infarction. 140
RELEVANCE OF CORONARY MICROVASCULAR FLOW IMPAIRMENT TO LONG TERM REMODELING AND SYSTOLIC DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY 136
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany 135
Right ventricular infarction: clinical, hemodynamic, mono- and two-dimensional echocardiographic features. 134
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 132
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. 132
Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy 132
Cardiomiopatie, Miocarditi e Pericarditi 131
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 129
THE ITALIAN REGISTRY FOR HYPERTROPHIC CARDIOMYOPATHY: A NATIONWIDE SURVEY 129
MAXIMUM LEFT VENTRICULAR THICKNESS AND RISK OF SUDDEN DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 128
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy 127
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. 126
Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening 125
'End-stage' hypertrophic cardiomyopathy: from mystery to model 124
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy 123
Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy 123
RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSESSED BY SIGNAL AVERAGED P WAVE DURATION 122
An expert consensus document on the management of cardiovascular manifestations of Fabry disease 122
Stage-specific therapy for hypertrophic cardiomyopathy 122
Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy 121
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 121
IMPACT OF ATRIAL FIBRILLATION ON THE CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY 120
EPIDEMIOLOGY OF HYPERTROPHIC CARDIOMYOPATHY-RELATED DEATH: REVISITED IN A LARGE NON- REFERRAL-BASED PATIENT POPULATION 120
HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY: CLINICAL COURSE AND OUTCOME IN AN UNSELECTED REGIONAL POPULATION 119
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis 117
TRANSIENT ASYMMETRIC VENTRICULAR SEPTAL HYPERTROPHY IN THE NEWBORN UNASSOCIATED WITH MATERNAL DIABETES 115
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy 113
THE NEED FOR EUROPEAN REGISTRIES IN INHERITED CARDIOMYOPATHIES 112
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy 112
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy) 111
CARDIOMIOPATIA IPERTROFICA 110
Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy 110
Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy 109
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes 109
Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanism and clinical consequences 102
EFFECT OF VERAPAMIL ON ABSOLUTE MYOCARDIAL BLOOD FLOW IN HYPERTROPHIC CARDIOMYOPATHY 101
Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy 101
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. 101
CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY IN A NON SELECTED POPULATION. EXPERIENCE OF THE ITALIAN MULTICENTER CARDIOMYOPATHY STUDY 100
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy 99
CLINICAL UTILITY AND SAFETY OF EXERCISE TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 99
Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management 98
RISK FACTORS AND STRATIFICATION FOR SUDDEN CARDIAC DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 96
PROGNOSTIC VALUE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA AND THE POTENTIAL ROLE OF AMIODARONE TREATMENT IN HYPERTROPHIC CARDIOMIYOPATHY: ASSESSMENT IN AN UNSELECTED NON-REFERRAL BASEDE PATIENT POPULATION 96
Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy 95
Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy 92
NEW CONCEPTS IN HYPERTROPHIC CARDIOMYOPATHIES 90
DIASTOLIC TIME INTERVALS BEFORE AN AFTER NADOLOL IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 90
Totale 15.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.753
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.753
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.042 0 0 0 0 0 180 80 156 139 281 66 140
2021/2022723 32 33 66 28 29 43 29 46 46 36 151 184
2022/20231.694 169 272 89 95 131 315 245 69 220 14 61 14
2023/2024590 23 72 118 36 38 78 18 109 15 32 20 31
2024/20254.453 165 481 267 680 1.294 561 63 305 198 132 168 139
2025/20262.991 478 760 436 719 572 26 0 0 0 0 0 0
Totale 15.733